Daclizumab - Wikipedia
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab …
ZENAPAX (daclizumab) is an immunosuppressive, humanized IgG1 monoclonal antibody produced by recombinant DNA technology that binds specifically to the alpha subunit (p55 …
Daclizumab (Zenapax，达昔单抗) - 仅供科研 | CD25阻断剂 | MCE
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to …
Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including …
Daclizumab: Uses, Interactions, Mechanism of Action | DrugBank …
2005年6月13日 · Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response …
Zenapax说明书-出境医
赛尼哌 ®（达珠单抗）是一种免疫抑制，人源化的IgG1单克隆通过重组DNA技术产生的抗体特异性结合的α亚基（P55α，CD25，或TAC亚基）人高亲和力的白细胞介素-2（IL-2）受体在活化的 …
赛尼哌说明书 (抗Tac单抗注射液) 赛尼哌副作用@用药助手
本品含有的活性成份抗Tac单抗是一种重组并人源化的IgG1（G亚型兔免疫球蛋白）抗Tac抗体，其功能类似于白细胞介素-2 (IL-2)受体拮抗剂。 与高亲和力的IL-2受体复合物 (在激活的T细胞表 …
Zenapax | European Medicines Agency (EMA)
Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including …
ZENAPAX (DACLIZUMAB) - 美国FDA药品数据库 - 药物在线
药品名称:ZENAPAX,活性成分:DACLIZUMAB,剂型:VIAL,规格:25MG/VIAL,药品注册申请号:103749,产品号:001
Zenapax（daclizumab）_急性排斥_肾脏移植
2003年8月31日 · Zenapax是特异性很强的抗IL-2R的单克隆抗体，有效地与IL-2竞争，从而抑制IL-2启动的T淋巴细胞增殖反应。 动物及临床试验表明，Zenapax具有选择性地免疫抑制效果， …
- 某些结果已被删除